Acasti Pharma Inc ACST

NAS: ACST | ISIN: CA00430K4028   17/05/2024
2,690 USD (-2,53%)
(-2,53%)   17/05/2024

10 juli 2023 · Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH Patients · Persbericht

7 juli 2023 · Acasti Pharma Announces 1-for-6 Reverse Stock Split · Persbericht

5 juli 2023 · Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023 · Persbericht

23 juni 2023 · Acasti Pharma Reports Fiscal Year 2023 Operational Results · Persbericht

22 juni 2023 · Acasti Announces Appointment of New Scientific Advisory Board Members · Persbericht

17 mei 2023 · Acasti to Participate in the Lytham Partners Spring 2023 Investor Conference · Persbericht

8 mei 2023 · Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025 · Persbericht

4 april 2023 · Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND · Persbericht

4 april 2023 · Acasti Announces Appointment of Prashant Kohli as CEO · Persbericht

30 maart 2023 · Acasti Pharma Inc. Announces the Resignation of a Director · Persbericht

13 maart 2023 · Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange · Persbericht

8 maart 2023 · Acasti Pharma to Participate in Oppenheimer 33rd Annual Healthcare Conference · Persbericht

28 februari 2023 · Acasti Pharma Recognizes Rare Disease Day · Persbericht

7 februari 2023 · Acasti Pharma to Report Third Quarter 2023 Financial Results on Tuesday, February 14, 2023 · Persbericht

Mijn selecties